Talcum Powder

Quick Answer: The talcum powder lawsuit statute of limitations typically runs one to six years from the date of diagnosis, depending on your state and whether that state applies a "discovery rule." Missing your state's deadline can bar your claim entirely, so confirming your exact filing window with an attorney as soon as possible is [...]

Quick Answer: As of July 2026, Johnson & Johnson's talc bankruptcy strategy has failed for a third time, and talcum powder trials are actively resuming in state and federal courts. Settlement amounts vary widely by diagnosis severity, and claimants with ovarian cancer or mesothelioma diagnoses linked to long-term talc use may still qualify to file. [...]

An updated look at the J&J talcum powder MDL: pending claim counts, the March 2026 Lancet retraction, June 2026's split bellwether verdicts, the reduced punitive damages ruling, and where settlement talks stand.

Update — 30 August 2026: On 27 July 2026 Johnson & Johnson proposed a $5.5 billion settlement, following a federal judge’s dismissal of the Red River Talc bankruptcy in March 2026. The proposal has not been finalised or approved. Important for mesothelioma claimants: that proposal is directed at ovarian cancer claims. Talc mesothelioma claims are [...]

Decades of scientific research, the IARC's 2024 Group 1 carcinogen reclassification, and J&J's failed bankruptcy attempts have reshaped the talcum powder lawsuit landscape in 2026. Learn what the science says, who qualifies, what settlements look like, and how to file a claim.

Quick Answer: The talcum powder lawsuit involves claims that Johnson & Johnson's talc-based products caused ovarian cancer or mesothelioma. Settlement amounts vary widely by diagnosis severity, and eligibility generally requires documented long-term product use plus a qualifying cancer diagnosis. Johnson & Johnson's bankruptcy strategy remains unresolved as of 2026, so no global settlement has [...]

Quick Answer: The talcum powder lawsuit update for August 2026: J&J's third bankruptcy attempt was dismissed March 31, 2025, and the company has since proposed a new $5.5 billion civil settlement covering ~76,000 ovarian cancer claims (announced July 27, 2026). The federal MDL-2738 now holds ~69,000 pending cases—the largest active MDL in the country. Women [...]